Endo Health Solutions needs a shot in the arm, now that its lead drug Lidoderm faces generic competition. And Endo may have found just that. The has company inked a deal to buy Canada's Paladin Labs for $1.6 billion.
We know Reckitt Benckiser is shopping its pharma unit. We also know that Shire is scouting for deals. Does it follow that Shire may bid on RB Pharma? Logically, yes. Practically? Maybe.
Terumo is expanding its presence in Turkey with the acquisition of a distributor of blood bank-related medical equipment.
Irish CRO Venn Life Sciences has agreed to trade nearly $1 million of stock for Germany's CRM Clinical Trials, a move that will stretch its reach into one of Europe's largest research markets.
It took close to 5 months, but Boston Scientific has closed its $275 million bid for C.R. Bard's electrophysiology business, which will help in its continued fight to rebound and return to robust revenue growth.
With a plummeting share price and grim prospects for its lead drug, Ariad Pharmaceuticals is adopting a shareholder rights plan to deter would-be corporate raiders, a move to protect what little value it has left.
After spending $8.7 billion on Bausch + Lomb, Canada's Valeant is hardly done dealmaking, CEO Michael Pearson said, telling analysts Valeant is on the lookout for cash deals to expand its pipeline and is keeping its ears open to a "merger of equals."
Outsourcing magnate inVentiv Health is padding its patient-adherence offerings, snapping up Catalina Health and merging the company with its Adheris subsidiary, a move it said creates the nation's largest provider of such services.
Just a few days ago, we learned that Dendreon is looking to woo a buyer. The question now is whether the struggling drugmaker can find a suitor to take on its baggage.
Teleflex will snatch up Texas-based Vidacare for $262.5 million to add that company's inside-the-bone/vascular access devices to its own product roster.